Article metrics

Original research
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

 

Online download statistics by month:

Online download statistics by month: October 2021 to December 2021

AbstractFullPdf
Oct 202111841194369
Nov 2021674675187
Dec 202120920978
Total20672078634